CN104703592A - 治疗轻度和中度阿尔茨海默病的方法 - Google Patents

治疗轻度和中度阿尔茨海默病的方法 Download PDF

Info

Publication number
CN104703592A
CN104703592A CN201380051206.0A CN201380051206A CN104703592A CN 104703592 A CN104703592 A CN 104703592A CN 201380051206 A CN201380051206 A CN 201380051206A CN 104703592 A CN104703592 A CN 104703592A
Authority
CN
China
Prior art keywords
day
subject
phenoxy
hydrochloride
achei
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380051206.0A
Other languages
English (en)
Chinese (zh)
Inventor
C·奥兰迪
D·J·克拉克
I·M·格里梅斯
M·C·瓦尔卡西-洛佩兹
M·J·考斯图拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
vTv Therapeutics LLC
Original Assignee
Trans Tech Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trans Tech Pharma Inc filed Critical Trans Tech Pharma Inc
Priority to CN201910466681.3A priority Critical patent/CN110292638A/zh
Publication of CN104703592A publication Critical patent/CN104703592A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
CN201380051206.0A 2012-10-05 2013-10-02 治疗轻度和中度阿尔茨海默病的方法 Pending CN104703592A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910466681.3A CN110292638A (zh) 2012-10-05 2013-10-02 治疗轻度和中度阿尔茨海默病的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261710229P 2012-10-05 2012-10-05
US61/710,229 2012-10-05
PCT/US2013/062964 WO2014055588A1 (en) 2012-10-05 2013-10-02 Treatment of mild and moderate alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910466681.3A Division CN110292638A (zh) 2012-10-05 2013-10-02 治疗轻度和中度阿尔茨海默病的方法

Publications (1)

Publication Number Publication Date
CN104703592A true CN104703592A (zh) 2015-06-10

Family

ID=49354960

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380051206.0A Pending CN104703592A (zh) 2012-10-05 2013-10-02 治疗轻度和中度阿尔茨海默病的方法
CN201910466681.3A Pending CN110292638A (zh) 2012-10-05 2013-10-02 治疗轻度和中度阿尔茨海默病的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910466681.3A Pending CN110292638A (zh) 2012-10-05 2013-10-02 治疗轻度和中度阿尔茨海默病的方法

Country Status (15)

Country Link
EP (1) EP2903606A1 (https=)
JP (2) JP6566868B2 (https=)
KR (1) KR20150064743A (https=)
CN (2) CN104703592A (https=)
AU (2) AU2013327450B2 (https=)
BR (1) BR112015007641A8 (https=)
CA (1) CA2886785C (https=)
EA (1) EA201590687A1 (https=)
HK (1) HK1207004A1 (https=)
IL (1) IL237730B (https=)
IN (1) IN2015DN03734A (https=)
MX (1) MX377733B (https=)
NZ (2) NZ705813A (https=)
SG (2) SG11201502210VA (https=)
WO (1) WO2014055588A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190823A1 (en) * 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
JP7464591B2 (ja) 2018-10-10 2024-04-09 ブイティーブイ・セラピューティクス・エルエルシー ［３－（４－｛２－ブチル－１－［４－（４－クロロ－フェノキシ）－フェニル］－１ｈ－イミダゾール－４－イル｝－フェノキシ）－プロピル］－ジエチル－アミンの代謝産物
WO2020086388A1 (en) * 2018-10-22 2020-04-30 Vtv Therapeutics Llc Glucokinase activator compositions for the treatment of cognitive impairment
JP7327788B2 (ja) * 2019-08-06 2023-08-16 学校法人福岡大学 糖化産物生成抑制剤及び医薬組成物
CN114031687B (zh) * 2021-11-12 2022-06-07 深圳市人民医院 靶向rage的纳米抗体及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4481011B2 (ja) * 2002-03-05 2010-06-16 トランス テック ファーマ，インコーポレイテッド リガンドのｒａｇｅとの相互作用を阻害する単環式および二環式アゾール誘導体
EP1635823A1 (en) * 2003-05-20 2006-03-22 TransTech Pharma Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
EP1707203A1 (en) * 2005-04-01 2006-10-04 Bioprojet Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
JP2010523559A (ja) * 2007-04-05 2010-07-15 トランス テック ファーマ，インコーポレイテッド ［３−（４−｛２−ブチル−１−［４−（４−クロロ−フェノキシ）−フェニル］−１ｈ−イミダゾール−４−イル｝−フェノキシ）−プロピル］−ジエチルアミンの結晶形態
CN101663280A (zh) * 2007-04-05 2010-03-03 转化技术制药公司 [3-(4-{2-丁基-1-[4-(4-氯-苯氧基)-苯基]-1h-咪唑-4-基}-苯氧基)-丙基]-二乙基-胺的晶型ⅰ和ⅱ
US20100254983A1 (en) * 2007-06-07 2010-10-07 Ann Marie Schmidt Uses of rage antagonists for treating obesity and related diseases
US20090221554A1 (en) * 2008-02-28 2009-09-03 Zenyaku Kogyo Kabushiki Kaisha Method of treating cognitive impairment
US8933040B2 (en) * 2010-11-08 2015-01-13 Craig A. Coburn Selective glycosidase inhibitors and uses thereof

Also Published As

Publication number Publication date
NZ705813A (en) 2018-02-23
HK1207004A1 (zh) 2016-01-22
AU2013327450A1 (en) 2015-05-14
JP2019163301A (ja) 2019-09-26
EP2903606A1 (en) 2015-08-12
AU2018203434A1 (en) 2018-06-07
KR20150064743A (ko) 2015-06-11
IN2015DN03734A (https=) 2015-09-18
NZ739521A (en) 2019-06-28
CA2886785A1 (en) 2014-04-10
JP6894940B2 (ja) 2021-06-30
CN110292638A (zh) 2019-10-01
BR112015007641A2 (pt) 2017-07-04
MX377733B (es) 2025-03-11
MX2015003732A (es) 2015-09-23
BR112015007641A8 (pt) 2018-04-03
SG11201502210VA (en) 2015-04-29
EA201590687A1 (ru) 2015-09-30
JP2015535850A (ja) 2015-12-17
IL237730B (en) 2018-10-31
SG10201702648YA (en) 2017-04-27
CA2886785C (en) 2022-06-07
WO2014055588A1 (en) 2014-04-10
AU2013327450B2 (en) 2018-07-12
JP6566868B2 (ja) 2019-08-28

Similar Documents

Publication Publication Date Title
US20250082651A1 (en) Ganaxolone for use in treating genetic epileptic disorders
JP2019163301A (ja) 軽度および中等度アルツハイマー病の処置
US12036190B2 (en) Methods and compositions for the treatment of cytoplasmic glycogen storage disorders
KR102486434B1 (ko) 바독솔론 메틸 또는 이의 유사체를 사용하는 알포트 증후군의 치료 방법
AU2006226811B2 (en) Dosage regimen for the treatment of a traumatic brain injury with progesterone
US8455468B2 (en) Methods for the treatment of a traumatic central nervous system injury
US9937182B2 (en) Therapeutic strategies for the treatment of preeclampsia
Ueki et al. Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry)
JP2017078085A (ja) 併用療法
US20190142803A1 (en) Treatment of Mild and Moderate Alzheimer's Disease
Pringle et al. Severe bradycardia due to interaction of timolol eye drops and verapamil
JP2018138572A (ja) 疾患および障害を検出、治療、および予防するための組成物および方法
Walters et al. Early clinical experience with the novel NMDA receptor antagonist CNS 5161
HK40009571A (zh) 治疗轻度和中度阿尔茨海默病的方法
EP4477224A1 (en) Pharmaceutical composition comprising allopurinol, febuxostat, or a pharmaceutically acceptable salt thereof for preventing or treating cardiovascular disease of subject having high blood uric acid level
Özbay et al. Role of Soluble Fractalkine, GFAP and CD163 in Cognitive Functions After Open Heart Surgery in Diabetic and Non-diabetic Patients.
Zaremba-Pechmann et al. Ronald Dahl, Michael Engel b, Daniel Dusser c, David Halpin d, Huib AM Kerstjens e
CN105250268B (zh) 厄贝沙坦组合物及其在制备治疗急性肾损伤的药物中的应用
Clough et al. Effect of inflammatory mediators on the developing micro circulation of the rabbit ear chamber
HK40061328A (en) A bruton's tyrosine kinase inhibitor for use in the treatment of chronic spontaneous urticaria
WO2020169041A1 (zh) 含氨氯地平、氯噻酮和醛固酮受体拮抗剂的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: North Carolina

Applicant after: vTv Therapeutics LLC

Address before: North Carolina

Applicant before: TRANSTECH PHARMA, Inc.

COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM:

Free format text: CORRECT: APPLICANT; FROM: TRANSFORMATION TECHNOLOGY PHARMA, LLC TO: VTV THERAPEUTICS LLC

C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
CB02 Change of applicant information

Address after: North Carolina

Applicant after: VTVX Holdings I LLC

Address before: North Carolina

Applicant before: VTV THERAPEUTICS LLC

COR Change of bibliographic data
TA01 Transfer of patent application right

Effective date of registration: 20151130

Address after: North Carolina

Applicant after: VTV THERAPEUTICS LLC

Address before: North Carolina

Applicant before: VTVX Holdings I LLC

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1207004

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20150610

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1207004

Country of ref document: HK